CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
22 hedge funds and large institutions have $16.1M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
2.96% less ownership
Funds ownership: 36.78% → 33.82% (-3%)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Holders
22
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$253K | |
| 2 | +$204K | |
| 3 | +$195K | |
| 4 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$32K |
| 5 |
AP
Atwood & Palmer
Kansas City,
Missouri
|
+$21K |
Top Sellers
| 1 | -$892K | |
| 2 | -$491K | |
| 3 | -$367K | |
| 4 |
LPL Financial
San Diego,
California
|
-$121K |
| 5 |
Citigroup
New York
|
-$31.7K |